Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 3

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

NCT07177352 · View on ClinicalTrials.gov ↗

Study Summary

This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.

Conditions Studied

Interventions

  • OTHER No Intervention

Study Locations (20)

Florida

  • JEM Research LLC — Atlantis
  • K2 Medical Research-Winter Garden — Clermont
  • K2 Medical Research - The Villages — Lady Lake
  • K2 Medical Research, LLC — Maitland
  • Visionary Investigators Network- Neurology Aventura — Miami
  • Renstar Medical Research — Ocala
  • Charter Research - Winter Park/Orlando — Orlando
  • Conquest Research - Lake Nona — Orlando
  • Alzheimer's Research and Treatment Center — Stuart

California

  • Sun Valley Research Center, Inc. — Imperial
  • Inglewood Clinicals — Inglewood
  • Irvine Center for Clinical Research — Irvine
  • Healthy Brain Clinic — Long Beach
  • Oakland Clinical — Oakland
  • Riverside Clinical — Riverside
  • Syrentis Clinical Research — Santa Ana
  • Cenexel California Neuroscience Research, LLC — Sherman Oaks

Arizona

  • Banner Alzheimer?s Institute — Phoenix
  • Banner Sun Health Research Institute — Sun City

Connecticut

  • Yale University — New Haven

Trial Details

FieldValue
Enrollment Target 13,000 participants
Start Date 2025-07-02
Est. Completion 2035-07-31
Phase Phase 3

Sponsor

Hoffmann-La Roche

758 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07177352

The ClinicalTrials.gov registry entry for NCT07177352 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 13,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 758 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 1 intervention — of which No Intervention is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07177352 reports 20 study locations spanning 4 distinct geographic areas — top geographies include Florida, California, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07177352 about?

NCT07177352 is a clinical study titled "Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies". This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.

What is the current status of trial NCT07177352?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 13,000 participants. The study started on 2025-07-02. Estimated completion is 2035-07-31.

What conditions does trial NCT07177352 study?

This clinical trial studies the following conditions: Alzheimers Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07177352?

The interventions under investigation include: No Intervention (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07177352?

This trial is sponsored by Hoffmann-La Roche, which has 758 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07177352 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial